Journal article
Retinal vascular changes following intravitreal ranibizumab injections for neovascular AMD over a 1-year period
SS Wickremasinghe, J Xie, RH Guymer, TY Wong, R Kawasaki, S Qureshi
Eye Basingstoke | NATURE PUBLISHING GROUP | Published : 2012
DOI: 10.1038/eye.2012.72
Abstract
Purpose: To assess retinal vascular calibre changes in eyes with neovascular age-related macular degeneration (AMD), treated with intravitreal anti-vascular endothelial growth factor agents, over a 1-year period and compare any such changes to untreated fellow eyes. Methods: Treatment naïve patients with neovascular AMD received three consecutive intravitreal injections of ranibizumab, followed by a pro re nata dosing regimen up to 1 year, with the aim of maintaining a 'fluid-free' macula. Retinal arteriolar and venular calibre was measured from digital fundus photographs at baseline and at three monthly intervals to 1 year, and summarised as central retinal artery equivalent (CRAE) and cent..
View full abstractGrants
Awarded by Novartis
Funding Acknowledgements
This study was partially funded by a National Health and Medical Research Council grant, 52993. Drs Guymer and Wong are on advisory boards of Novartis and Pfizer and have received research funding, speaking fees, travel and accommodation from either/both companies. The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian Government. This study was approved by the Human Research and Ethics Committee of the Royal Victorian Eye and Ear Hospital (RVEEH).